首頁 › 三陰性乳癌 › 賓夕法尼亞州 › Philadelphia
Philadelphia, PA 的 三陰性乳癌 臨床試驗
13 項針對 三陰性乳癌 的研究正在 Philadelphia（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
招募中1/2 期
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
招募中1 期
- Sidney Kimmell Cancer Center - Jefferson Health, Philadelphia
Study of AVZO-021 in Patients With Advanced Solid Tumors
招募中1/2 期
- Avenzo Therapeutics Recruiting Site, Philadelphia
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
招募中3 期
- Sidney Kimmel Cancer Center at Jefferson ( Site 0049), Philadelphia
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
招募中2 期
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
招募中3 期
- University of Pennsylvania Abramson Cancer Center, Philadelphia
- Lankenau Medical Center, Wynnewood · 距離 7 英里
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
招募中1 期
- Normunity Investigational Site, Philadelphia
- Normunity Investigational Site, Philadelphia
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
招募中2/3 期
- Abramson Cancer Center of The University of Pennsylvania, Philadelphia
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
招募中2 期
- University of Pennsylvania (U Penn), Philadelphia
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
招募中2 期
- University of Pennsylvania-Abramson Cancer Center, Philadelphia
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
招募中2 期
- University of Pennsylvania-Abramson Cancer Center, Philadelphia
Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer
招募中
- Thomas Jefferson University Hospital, Philadelphia
Role of the Immune Environment in Response to Therapy in Breast Cancer
招募中觀察性研究
- Abramson Cancer Center, Philadelphia
其他城市的 三陰性乳癌 試驗
- Houston, TX42 項研究
- New York City, NY31 項研究
- Nashville, TN28 項研究
- Los Angeles, CA27 項研究
- Boston, MA26 項研究
- San Antonio, TX23 項研究
- St. Louis, MO21 項研究
- Arlington, VA20 項研究
- Atlanta, GA20 項研究
- Dallas, TX18 項研究
- Chicago, IL16 項研究
- Columbus, OH16 項研究
Philadelphia 的其他研究
- 癌症（所有類型）59 項研究
- 乳癌56 項研究
- 非小細胞肺癌51 項研究
- 轉移性癌症46 項研究
- 前列腺癌44 項研究
- 大腸直腸癌44 項研究
- 卵巢癌44 項研究
- 肺癌36 項研究
- 急性髓系白血病34 項研究
- 心臟衰竭31 項研究
- 子宮內膜癌28 項研究
- 憂鬱症26 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。